The Experts below are selected from a list of 1281 Experts worldwide ranked by ideXlab platform
Yutaka Kawakami - One of the best experts on this subject based on the ideXlab platform.
-
In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer
Cancer Gene Therapy, 2002Co-Authors: Takashi Endo, Masahiro Toda, Masahiko Watanabe, Yukihiko Iizuka, Tetsuro Kubota, Masaki Kitajima, Yutaka KawakamiAbstract:In this study, we investigated the therapeutic efficacy of a replication-conditional mutant HSV, G207, for the treatment of liver metastasis of colon carcinoma. Three liver metastasis models in syngeneic BALB/c mice were developed: (i) splenic injection, (ii) splenic and subcutaneous (s.c.) injection, and (iii) orthotopic implantation of CT26 colon carcinoma. In the splenic injection model, G207 was injected into the established splenic Tumor on day 7. In the splenic and s.c. injection model, G207 were injected into the established s.c. Tumor on days 5 and 8. In the orthotopic implantation model, a piece of CT26 Tumor tissue was transplanted onto the wall of the Cecum and G207 was injected in the established Cecum Tumor on day 7. On day 21 or 28, animals were sacrificed and liver metastases were evaluated. In all three models in immunocompetent mice, liver metastases were significantly reduced by intraTumoral inoculation with G207 compared to the control. In athymic mice, however, there was no significant therapeutic effect of intraTumoral inoculation with G207 on liver metastases. Tumor-specific cytotoxic T-lymphocyte responses were induced in mice treated with G207 in the orthotopic implantation model. These results suggest that intraTumoral inoculation of G207, as an in situ cancer vaccine, can be an effective approach against liver metastasis of colon cancer and the efficacy involves Tumor-specific T-cell responses.
Takashi Endo - One of the best experts on this subject based on the ideXlab platform.
-
In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer
Cancer Gene Therapy, 2002Co-Authors: Takashi Endo, Masahiro Toda, Masahiko Watanabe, Yukihiko Iizuka, Tetsuro Kubota, Masaki Kitajima, Yutaka KawakamiAbstract:In this study, we investigated the therapeutic efficacy of a replication-conditional mutant HSV, G207, for the treatment of liver metastasis of colon carcinoma. Three liver metastasis models in syngeneic BALB/c mice were developed: (i) splenic injection, (ii) splenic and subcutaneous (s.c.) injection, and (iii) orthotopic implantation of CT26 colon carcinoma. In the splenic injection model, G207 was injected into the established splenic Tumor on day 7. In the splenic and s.c. injection model, G207 were injected into the established s.c. Tumor on days 5 and 8. In the orthotopic implantation model, a piece of CT26 Tumor tissue was transplanted onto the wall of the Cecum and G207 was injected in the established Cecum Tumor on day 7. On day 21 or 28, animals were sacrificed and liver metastases were evaluated. In all three models in immunocompetent mice, liver metastases were significantly reduced by intraTumoral inoculation with G207 compared to the control. In athymic mice, however, there was no significant therapeutic effect of intraTumoral inoculation with G207 on liver metastases. Tumor-specific cytotoxic T-lymphocyte responses were induced in mice treated with G207 in the orthotopic implantation model. These results suggest that intraTumoral inoculation of G207, as an in situ cancer vaccine, can be an effective approach against liver metastasis of colon cancer and the efficacy involves Tumor-specific T-cell responses.
C.s. Costa - One of the best experts on this subject based on the ideXlab platform.
-
Gallstone ileus caused by a gallstone impacted at a Cecum neoplasm - A case report.
International journal of surgery case reports, 2020Co-Authors: N. Pratas, D. Salvador, C.s. CostaAbstract:ABSTRACT Background Gallstone ileus is an infrequent complication of biliary disease that produces a mechanical intestinal obstruction. It is caused by a gallstone passing through a bilio-digestive communication, usually a cholecystoduodenal fistula. The presence of neoplasms can decrease the bowel lumen size and may cause the gallstone to impact at the narrowing site. Case summary In this report, we present a unique case of gallstone ileus due to a gallstone impacted in a Cecum Tumor, causing obstruction at the level of the ileocecal valve. The patient needed an urgent right hemicolectomy to solve both his problems. The gallbladder and the enterobiliary fistula remained in situ. Discussion The clinical presentation is not always straightforward and sometimes the diagnosis is only made by imaging, mostly resorting to an abdominal CT. The mainstay of management is surgical relief of the gastrointestinal obstruction, with the surgical method being based on what is found intra-operatively and according to the patient general condition. Conclusion Although a rare disease, gallstone ileus should be suspected in elderly patients with intestinal obstruction and a previous history of biliary problems, keeping in mind that other conditions may be present and can alter the surgical treatment of choice.
Masaki Kitajima - One of the best experts on this subject based on the ideXlab platform.
-
In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer
Cancer Gene Therapy, 2002Co-Authors: Takashi Endo, Masahiro Toda, Masahiko Watanabe, Yukihiko Iizuka, Tetsuro Kubota, Masaki Kitajima, Yutaka KawakamiAbstract:In this study, we investigated the therapeutic efficacy of a replication-conditional mutant HSV, G207, for the treatment of liver metastasis of colon carcinoma. Three liver metastasis models in syngeneic BALB/c mice were developed: (i) splenic injection, (ii) splenic and subcutaneous (s.c.) injection, and (iii) orthotopic implantation of CT26 colon carcinoma. In the splenic injection model, G207 was injected into the established splenic Tumor on day 7. In the splenic and s.c. injection model, G207 were injected into the established s.c. Tumor on days 5 and 8. In the orthotopic implantation model, a piece of CT26 Tumor tissue was transplanted onto the wall of the Cecum and G207 was injected in the established Cecum Tumor on day 7. On day 21 or 28, animals were sacrificed and liver metastases were evaluated. In all three models in immunocompetent mice, liver metastases were significantly reduced by intraTumoral inoculation with G207 compared to the control. In athymic mice, however, there was no significant therapeutic effect of intraTumoral inoculation with G207 on liver metastases. Tumor-specific cytotoxic T-lymphocyte responses were induced in mice treated with G207 in the orthotopic implantation model. These results suggest that intraTumoral inoculation of G207, as an in situ cancer vaccine, can be an effective approach against liver metastasis of colon cancer and the efficacy involves Tumor-specific T-cell responses.
Tetsuro Kubota - One of the best experts on this subject based on the ideXlab platform.
-
In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer
Cancer Gene Therapy, 2002Co-Authors: Takashi Endo, Masahiro Toda, Masahiko Watanabe, Yukihiko Iizuka, Tetsuro Kubota, Masaki Kitajima, Yutaka KawakamiAbstract:In this study, we investigated the therapeutic efficacy of a replication-conditional mutant HSV, G207, for the treatment of liver metastasis of colon carcinoma. Three liver metastasis models in syngeneic BALB/c mice were developed: (i) splenic injection, (ii) splenic and subcutaneous (s.c.) injection, and (iii) orthotopic implantation of CT26 colon carcinoma. In the splenic injection model, G207 was injected into the established splenic Tumor on day 7. In the splenic and s.c. injection model, G207 were injected into the established s.c. Tumor on days 5 and 8. In the orthotopic implantation model, a piece of CT26 Tumor tissue was transplanted onto the wall of the Cecum and G207 was injected in the established Cecum Tumor on day 7. On day 21 or 28, animals were sacrificed and liver metastases were evaluated. In all three models in immunocompetent mice, liver metastases were significantly reduced by intraTumoral inoculation with G207 compared to the control. In athymic mice, however, there was no significant therapeutic effect of intraTumoral inoculation with G207 on liver metastases. Tumor-specific cytotoxic T-lymphocyte responses were induced in mice treated with G207 in the orthotopic implantation model. These results suggest that intraTumoral inoculation of G207, as an in situ cancer vaccine, can be an effective approach against liver metastasis of colon cancer and the efficacy involves Tumor-specific T-cell responses.